AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Analyst Ratings Changes
A number of research firms recently issued reports on ABC. Robert W. Baird boosted their target price on shares of AmerisourceBergen from $179.00 to $187.00 in a research report on Thursday, May 5th. Morgan Stanley reduced their price target on shares of AmerisourceBergen from $178.00 to $175.00 and set an "equal weight" rating for the company in a research report on Friday, May 27th. Deutsche Bank Aktiengesellschaft raised shares of AmerisourceBergen from a "hold" rating to a "buy" rating and upped their price objective for the company from $167.00 to $178.00 in a research note on Tuesday, June 7th. Mizuho upped their price objective on shares of AmerisourceBergen from $139.00 to $162.00 in a research note on Thursday, May 5th. Finally, Cowen dropped their price objective on shares of AmerisourceBergen from $171.00 to $170.00 and set an "outperform" rating for the company in a research note on Thursday, June 9th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $173.45.
AmerisourceBergen Stock Up 1.8 %
AmerisourceBergen stock traded up $2.73 during mid-day trading on Friday, reaching $150.50. 880,952 shares of the company's stock were exchanged, compared to its average volume of 994,437. The company has a market cap of $31.52 billion, a P/E ratio of 17.26, a P/E/G ratio of 1.67 and a beta of 0.48. AmerisourceBergen has a twelve month low of $113.68 and a twelve month high of $167.19. The company has a quick ratio of 0.55, a current ratio of 0.92 and a debt-to-equity ratio of 8.96. The company has a fifty day moving average of $143.29 and a 200-day moving average of $147.97.
AmerisourceBergen (NYSE:ABC - Get Rating) last released its earnings results on Wednesday, August 3rd. The company reported $2.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.56 by $0.06. The company had revenue of $60.06 billion for the quarter, compared to analyst estimates of $59.03 billion. AmerisourceBergen had a net margin of 0.78% and a return on equity of 350.60%. The firm's quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the business earned $2.16 EPS. Sell-side analysts expect that AmerisourceBergen will post 10.99 EPS for the current year.
AmerisourceBergen Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 29th. Shareholders of record on Monday, August 15th will be issued a dividend of $0.46 per share. The ex-dividend date of this dividend is Friday, August 12th. This represents a $1.84 dividend on an annualized basis and a yield of 1.22%. AmerisourceBergen's dividend payout ratio (DPR) is presently 21.10%.
Insiders Place Their Bets
In other news, CEO Steven H. Collis sold 11,480 shares of the firm's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $144.25, for a total value of $1,655,990.00. Following the sale, the chief executive officer now directly owns 205,178 shares in the company, valued at approximately $29,596,926.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 34,440 shares of company stock worth $4,911,374 in the last ninety days. 28.40% of the stock is owned by corporate insiders.